ANEBULO PHARMAC. Aktie News & Nachrichten
[WKN: A3CM1D | Symbol: 214]Realtimekurs
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. Its product candidate, Selonabant, is a small molecule antagonist of cannabinoid binding receptor type-1. The company was founded by Joseph F. Lawler on April 23, 2020 and is headquartered in Lakeway, TX.
Es konnten keine Nachrichten über ANEBULO PHARMAC. gefunden werden.